Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Audio By Carbonatix

FREMONT, Calif.--(BUSINESS WIRE)--Feb 17, 2026--

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46 th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott Copley Place in Boston, MA.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X ( Twitter ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20260217655785/en/

CONTACT: Investor Relations:

Caroline Corner

[email protected]

415-202-5678

Media:

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS HEALTH TECHNOLOGY MANAGED CARE BIOTECHNOLOGY

SOURCE: Personalis, Inc.

Copyright Business Wire 2026.

PUB: 02/17/2026 04:01 PM/DISC: 02/17/2026 04:02 PM

http://www.businesswire.com/news/home/20260217655785/en